$REGN: Regeneron Reports Q3 2026: Revenue Up 36% to $5.1B, Non-GAAP EPS Jumps

$REGN

$REGN – Regeneron Reports Q3 2026: Revenue Up 36% to $5.1B, Non-GAAP EPS Jumps 70% to $20.07

REGENERON PHARMACEUTICALS, INC.

2026-10-30 00:00:00 UTC · SEC_8K · All $REGN

?? Positive AI Sentiment (+6.8 / 10)

Total revenues increased 36% year-over-year to $5.1 billion.
GAAP diluted EPS grew 35% to $18.45; non-GAAP diluted EPS surged 70% to $20.07.
EYLEA HD U.S. net sales rose 62% to $699 million; global Dupixent sales up 35% to $6.5 billion.

Observed market reaction after signal

Peak +7.42%